{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/65736d39d32e730012c98919/65bd370851c4a10016478ed6?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Genome Interpretation, Nanoparticles, Gene Therapy, 2024 IPOs; Nautilus Biotechnology","description":"<p><strong>Episode 7 (February 2, 2024):</strong> Simplify Genomics launches genome interpretation platform, COUR’s nanoparticles for autoimmunity, gene replacement therapy for heart condition, CG Oncology and ArriVent IPOs; an interview with Nautilus Biotechnology co-founders, Sujal Patel and Parag Mallick.</p><p>Listed below are key references to the <em>GEN</em> stories, media and other items discussed in this episode of <em>Touching Base</em>:</p><p><br></p><p><a href=\"https://www.genengnews.com/topics/translational-medicine/human-longevity-spin-out-simplify-genomics-aims-to-tap-into-variant-interpretation-market/\" rel=\"noopener noreferrer\" target=\"_blank\">Human Longevity Spin-Out Aims to Tap into Variant Interpretation Market</a></p><p>By Uduak Thomas, <em>GEN</em>, January 31st, 2024</p><p><br></p><p><a href=\"https://www.genengnews.com/topics/drug-discovery/light-my-fire-cour-raises-105m-series-a-to-advance-tolerogenic-nanoparticles-for-autoimmunity/\" rel=\"noopener noreferrer\" target=\"_blank\">Light My Fire: COUR Raises $105M Series A to Advance Tolerogenic Nanoparticles for Autoimmunity</a></p><p>By Jonathan Grinstein, <em>GEN Edge</em>, January 30th, 2024</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/translational-medicine/gene-replacement-therapy-halts-fatal-arrhythmogenic-condition-in-mice/\" rel=\"noopener noreferrer\" target=\"_blank\">Gene Replacement Therapy Halts Fatal Arrhythmogenic Condition in Mice</a></p><p><em>GEN</em>, January 30th, 2024</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/cancer/stockwatch-ipo-revival-cg-oncology-arrivent-raise-a-combined-555m/\" rel=\"noopener noreferrer\" target=\"_blank\">StockWatch: IPO Revival? CG Oncology, ArriVent Raise a Combined $555M</a></p><p>By Alex Philippidis, <em>GEN Edge</em>, January 28th, 2024</p><p><br></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>","author_name":"Genetic Engineering & Biotechnology News (GEN)"}